Abstract

Intensive therapies are often medically indicated for older adults with hematologic malignancies. These may include induction chemotherapy for acute myeloid leukemia (AML), as well as autologous hematopoietic cell transplant (autoHCT) and allogeneic hematopoietic cell transplant (alloHCT). However, it is not always clear how to best deliver these therapies, in terms of determining treatment eligibility, as well as adjusting or adding supportive measures to the treatment plan to maximize successful outcomes. Beyond performance status and presence of comorbidities, comprehensive geriatric assessment and individual geriatric metrics have increasingly been used to prognosticate in these settings and may offer the best approach to personalizing therapy. In the setting of AML induction, evidence supports the use of measures of physical function as independent predictors of survival. For patients undergoing alloHCT, functional status, as measured by instrumental activities of daily living (IADL) and gait speed, may be an important pretransplant assessment. IADL has also been associated with post-autoHCT morbidity and mortality. Current best practice includes assessment of relevant geriatric metrics prior to intensive therapy, and work is ongoing to develop complementary interventions.

References

References
1.
Surveillance, Epidemiology and End Results Program. Cancer Statistics Factsheets. seer.cancer.gov/factsheets. Accessed 25 July 2019
.
2.
Krug
U
,
Röllig
C
,
Koschmieder
A
, et al;
Study Alliance Leukemia Investigators
.
Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes
.
Lancet
.
2010
;
376
(
9757
):
2000
-
2008
.
3.
Kantarjian
H
,
Ravandi
F
,
O’Brien
S
, et al
.
Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia
.
Blood
.
2010
;
116
(
22
):
4422
-
4429
.
4.
Röllig
C
,
Thiede
C
,
Gramatzki
M
, et al;
Study Alliance Leukemia
.
A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial
.
Blood
.
2010
;
116
(
6
):
971
-
978
.
5.
Wheatley
K
,
Brookes
CL
,
Howman
AJ
, et al;
United Kingdom National Cancer Research Institute Haematological Oncology Clinical Studies Group and Acute Myeloid Leukaemia Subgroup
.
Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials
.
Br J Haematol
.
2009
;
145
(
5
):
598
-
605
.
6.
Klepin
HD
,
Geiger
AM
,
Tooze
JA
, et al
.
The feasibility of inpatient geriatric assessment for older adults receiving induction chemotherapy for acute myelogenous leukemia
.
J Am Geriatr Soc
.
2011
;
59
(
10
):
1837
-
1846
.
7.
Klepin
HD
,
Ritchie
EK
,
Sanford
BL
, et al
.
Feasibility of geriatric assessment for older adults with acute myeloid leukemia (AML) receiving intensive chemotherapy on a cooperative group trial: CALGB 361006 (Alliance)
.
J Clin Oncol
.
2014
;
32
(
15 suppl
):
7102
.
8.
Katz
S
,
Downs
TD
,
Cash
HR
,
Grotz
RC
.
Progress in development of the index of ADL
.
Gerontologist
.
1970
;
10
(
1
):
20
-
30
.
9.
Lawton
MP
,
Brody
EM
.
Assessment of older people: self-maintaining and instrumental activities of daily living
.
Gerontologist
.
1969
;
9
(
3
):
179
-
186
.
10.
Guralnik
JM
,
Simonsick
EM
,
Ferrucci
L
, et al
.
A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission
.
J Gerontol
.
1994
;
49
(
2
):
M85
-
M94
.
11.
Etienne
A
,
Esterni
B
,
Charbonnier
A
, et al
.
Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia
.
Cancer
.
2007
;
109
(
7
):
1376
-
1383
.
12.
Oran
B
,
Weisdorf
DJ
.
Survival for older patients with acute myeloid leukemia: a population-based study
.
Haematologica
.
2012
;
97
(
12
):
1916
-
1924
.
13.
Østgård
LS
,
Nørgaard
JM
,
Sengeløv
H
, et al
.
Comorbidity and performance status in acute myeloid leukemia patients: a nation-wide population-based cohort study
.
Leukemia
.
2015
;
29
(
3
):
548
-
555
.
14.
Tawfik
B
,
Pardee
TS
,
Isom
S
, et al
.
Comorbidity, age, and mortality among adults treated intensively for acute myeloid leukemia (AML)
.
J Geriatr Oncol
.
2016
;
7
(
1
):
24
-
31
.
15.
Giles
FJ
,
Borthakur
G
,
Ravandi
F
, et al
.
The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia
.
Br J Haematol
.
2007
;
136
(
4
):
624
-
627
.
16.
Malfuson
JV
,
Etienne
A
,
Turlure
P
, et al;
Acute Leukemia French Association (ALFA)
.
Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia
.
Haematologica
.
2008
;
93
(
12
):
1806
-
1813
.
17.
Djunic
I
,
Virijevic
M
,
Novkovic
A
, et al
.
Pretreatment risk factors and importance of comorbidity for overall survival, complete remission, and early death in patients with acute myeloid leukemia
.
Hematology
.
2012
;
17
(
2
):
53
-
58
.
18.
Sorror
ML
,
Storer
BE
,
Fathi
AT
, et al
.
Development and validation of a novel acute myeloid leukemia-composite model to estimate risks of mortality
.
JAMA Oncol
.
2017
;
3
(
12
):
1675
-
1682
.
19.
Wedding
U
,
Röhrig
B
,
Klippstein
A
,
Fricke
HJ
,
Sayer
HG
,
Höffken
K
.
Impairment in functional status and survival in patients with acute myeloid leukaemia
.
J Cancer Res Clin Oncol
.
2006
;
132
(
10
):
665
-
671
.
20.
Sherman
AE
,
Motyckova
G
,
Fega
KR
, et al
.
Geriatric assessment in older patients with acute myeloid leukemia: a retrospective study of associated treatment and outcomes
.
Leuk Res
.
2013
;
37
(
9
):
998
-
1003
.
21.
Deschler
B
,
Ihorst
G
,
Platzbecker
U
, et al
.
Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome
.
Haematologica
.
2013
;
98
(
2
):
208
-
216
.
22.
Klepin
HD
,
Geiger
AM
,
Tooze
JA
, et al
.
Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia
.
Blood
.
2013
;
121
(
21
):
4287
-
4294
.
23.
Timilshina
N
,
Breunis
H
,
Tomlinson
G
,
Brandwein
J
,
Alibhai
SM
.
Do quality of life, physical function, or the Wheatley index at diagnosis predict 1-year mortality with intensive chemotherapy in older acute myeloid leukemia patients?
Leuk Res
.
2016
;
47
:
142
-
148
.
24.
Elliot
K
,
Tooze
JA
,
Geller
R
, et al
.
The prognostic importance of polypharmacy in older adults treated for acute myelogenous leukemia (AML)
.
Leuk Res
.
2014
;
38
(
10
):
1184
-
1190
.
25.
DiNardo
CD
,
Pratz
K
,
Pullarkat
V
, et al
.
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
.
Blood
.
2019
;
133
(
1
):
7
-
17
.
26.
Alibhai
SM
,
Durbano
S
,
Breunis
H
, et al
.
A phase II exercise randomized controlled trial for patients with acute myeloid leukemia undergoing induction chemotherapy
.
Leuk Res
.
2015
;
S0145-2126(15)30365-9
.
27.
Kuhlman
P
,
Isom
S
,
Pardee
TS
, et al
.
Association between glycemic control, age, and outcomes among intensively treated patients with acute myeloid leukemia
.
Support Care Cancer
.
2019
27
(
8
):
2877
-
2884
.
28.
D’Souza
A
,
Fretham
C
.
Current use and outcome of hematopoietic stem cell transplantation: CIBMTR Summary Slides
,
2018. https://www.cibmtr.org. Accessed 25 July 2019
.
29.
Muffly
L
,
Pasquini
MC
,
Martens
M
, et al
.
Increasing use of allogeneic hematopoietic cell transplantation (HCT) in patients age 70 years and older: A CIBMTR study of trends and outcomes
.
Biol Blood Marrow Transplant
.
2016
;
22
(
3
):
S68
-
S69
.
30.
Sorror
ML
,
Storb
RF
,
Sandmaier
BM
, et al
.
Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation
.
J Clin Oncol
.
2014
;
32
(
29
):
3249
-
3256
.
31.
McClune
BL
,
Weisdorf
DJ
,
Pedersen
TL
, et al
.
Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome
.
J Clin Oncol
.
2010
;
28
(
11
):
1878
-
1887
.
32.
Sorror
M
,
Storer
B
,
Sandmaier
BM
, et al
.
Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation
.
Cancer
.
2008
;
112
(
9
):
1992
-
2001
.
33.
Coffey
DG
,
Pollyea
DA
,
Myint
H
,
Smith
C
,
Gutman
JA
.
Adjusting DLCO for Hb and its effects on the Hematopoietic Cell Transplantation-specific Comorbidity Index
.
Bone Marrow Transplant
.
2013
;
48
(
9
):
1253
-
1256
.
34.
Muffly
LS
,
Kocherginsky
M
,
Stock
W
, et al
.
Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients
.
Haematologica
.
2014
;
99
(
8
):
1373
-
1379
.
35.
Holmes
HM
,
Des Bordes
JK
,
Kebriaei
P
, et al
.
Optimal screening for geriatric assessment in older allogeneic hematopoietic cell transplantation candidates
.
J Geriatr Oncol
.
2014
;
5
(
4
):
422
-
430
.
36.
Lin
RJ
,
Shahrokni
A
,
Dahi
PB
, et al
.
Pretransplant comprehensive geriatric assessment in hematopoietic cell transplantation: a single center experience
.
Bone Marrow Transplant
.
2018
;
53
(
9
):
1184
-
1187
.
37.
Huang
LW
,
Huang
CY
,
Andreadis
C
, et al
.
Functional status is associated with outcomes after allogeneic stem cell transplantation for older patients with hematologic malignancies
.
Blood
.
2018
;
132
(
suppl 1
):
3599
.
38.
Deschler
B
,
Ihorst
G
,
Schnitzler
S
,
Bertz
H
,
Finke
J
.
Geriatric assessment and quality of life in older patients considered for allogeneic hematopoietic cell transplantation: a prospective risk factor and serial assessment analysis
.
Bone Marrow Transplant
.
2018
;
53
(
5
):
565
-
575
.
39.
Rodrigues
M
,
de Souza
PMR
,
de Oliveira Muniz Koch
L
,
Hamerschlak
N
.
The use of comprehensive geriatric assessment in older patients before allologeneic hematopoietic stem cell transplantation: a cross-sectional study [published online ahead of print 20 June 2019]
.
J Geriatr Oncol
.
doi:10.1016/j.jgo.2019.05.022
.
40.
Muffly
LS
,
Boulukos
M
,
Swanson
K
, et al
.
Pilot study of comprehensive geriatric assessment (CGA) in allogeneic transplant: CGA captures a high prevalence of vulnerabilities in older transplant recipients
.
Biol Blood Marrow Transplant
.
2013
;
19
(
3
):
429
-
434
.
41.
Olin
R
,
Andreadis
C
,
Martin
T
, et al
.
Comprehensive geriatric assessment identifies significant functional impairments in older hematopoietic cell transplant recipients
.
Biol Blood Marrow Transplant
.
2014
;
20
(
2
):
S65
-
S66
.
42.
Alousi
AM
,
Le-Rademacher
J
,
Saliba
RM
, et al
.
Who is the better donor for older hematopoietic transplant recipients: an older-aged sibling or a young, matched unrelated volunteer?
Blood
.
2013
;
121
(
13
):
2567
-
2573
.
43.
Randall
J
,
Keven
K
,
Atli
T
,
Ustun
C
.
Process of allogeneic hematopoietic cell transplantation decision making for older adults
.
Bone Marrow Transplant
.
2016
;
51
(
5
):
623
-
628
.
44.
Derman
BA
,
Kordas
K
,
Ridgeway
J
, et al
.
The Transplant Optimization Program (TOP): implementing a geriatric assessment (GA)-guided interdisciplinary clinic (IDC) prior to allogeneic hematopoietic cell transplantation (HCT) in older adults
.
J Clin Oncol
.
2019
;
37
(
15 suppl
):
7045
.
45.
Lin
RJ
,
Hilden
PD
,
Elko
TA
, et al
.
Burden and impact of multifactorial geriatric syndromes in allogeneic hematopoietic cell transplantation for older adults
.
Blood Adv
.
2019
;
3
(
1
):
12
-
20
.
46.
de Almeida
LB
,
Mira
PAC
,
Fioritto
AP
, et al
.
Functional capacity change impacts the quality of life of hospitalized patients undergoing hematopoietic stem cell transplantation
.
Am J Phys Med Rehabil
.
2019
;
98
(
6
):
450
-
455
.
47.
Mohammed
J
,
Smith
SR
,
Burns
L
, et al
.
Role of physical therapy before and after hematopoietic stem cell transplantation: White Paper Report
.
Biol Blood Marrow Transplant
.
2019
;
25
(
6
):
e191
-
e198
.
48.
Wong
FL
,
Francisco
L
,
Togawa
K
, et al
.
Long-term recovery after hematopoietic cell transplantation: predictors of quality-of-life concerns
.
Blood
.
2010
;
115
(
12
):
2508
-
2519
.
49.
Arora
M
,
Sun
C
,
Ness
K
, et al
.
Older survivors of allogeneic hematopoietic cell transplantation (HCT) with chronic graft vs. host disease (cGvHD) demonstrate higher risk of frailty as compared with autologous HCT recipients: a report from the Bone Marrow Transplant Survivor Study-2
.
Biol Blood Marrow Transplant
.
2015
;
21
(
2 suppl
):
S72
-
S73
.
50.
Auner
HW
,
Szydlo
R
,
Hoek
J
, et al
.
Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years
.
Bone Marrow Transplant
.
2015
;
50
(
2
):
209
-
215
.
51.
Sharma
M
,
Zhang
MJ
,
Zhong
X
, et al
.
Older patients with myeloma derive similar benefit from autologous transplantation
.
Biol Blood Marrow Transplant
.
2014
;
20
(
11
):
1796
-
1803
.
52.
Facon
T
,
Kumar
S
,
Plesner
T
, et al;
MAIA Trial Investigators
.
Daratumumab plus lenalidomide and dexamethasone for untreated myeloma
.
N Engl J Med
.
2019
;
380
(
22
):
2104
-
2115
.
53.
Mateos
MV
,
Dimopoulos
MA
,
Cavo
M
, et al;
ALCYONE Trial Investigators
.
Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma
.
N Engl J Med
.
2018
;
378
(
6
):
518
-
528
.
54.
Palumbo
A
,
Bringhen
S
,
Mateos
MV
, et al
.
Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report
.
Blood
.
2015
;
125
(
13
):
2068
-
2074
.
55.
Wildes
TM
,
Tuchman
SA
,
Klepin
HD
, et al
.
Geriatric assessment in older adults with multiple myeloma
.
J Am Geriatr Soc
.
2019
;
67
(
5
):
987
-
991
.
56.
Rosko
AE
,
Huang
Y
,
Benson
DM
, et al
.
Use of a comprehensive frailty assessment to predict morbidity in patients with multiple myeloma undergoing transplant
.
J Geriatr Oncol
.
2019
;
10
(
3
):
479
-
485
.
57.
Nawas
MT
,
Andreadis
C
,
Martin
TG
, et al
.
Limitation in patient-reported function is associated with inferior survival in older adults undergoing autologous hematopoietic cell transplantation
.
Biol Blood Marrow Transplant
.
2019
;
25
(
6
):
1218
-
1224
.
58.
Muchtar
E
,
Dingli
D
,
Kumar
S
, et al
.
Autologous stem cell transplant for multiple myeloma patients 70 years or older
.
Bone Marrow Transplant
.
2016
;
51
(
11
):
1449
-
1455
.
59.
Auner
HW
,
Iacobelli
S
,
Sbianchi
G
, et al
.
Melphalan 140 mg/m2 or 200 mg/m2 for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party
.
Haematologica
.
2018
;
103
(
3
):
514
-
521
.
60.
Ghilardi
G
,
Pabst
T
,
Jeker
B
, et al
.
Melphalan dose in myeloma patients ≥65 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multicentric observational registry study
.
Bone Marrow Transplant
.
2019
;
54
(
7
):
1029
-
1037
.
61.
Jantunen
E
,
Canals
C
,
Rambaldi
A
, et al;
EBMT Lymphoma Working Party
.
Autologous stem cell transplantation in elderly patients (> or =60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation registry
.
Haematologica
.
2008
;
93
(
12
):
1837
-
1842
.
62.
Lazarus
HM
,
Carreras
J
,
Boudreau
C
, et al;
Center For International Blood & Marrow Transplant Research (CIBMTR)
.
Influence of age and histology on outcome in adult non-Hodgkin lymphoma patients undergoing autologous hematopoietic cell transplantation (HCT): a report from the Center For International Blood & Marrow Transplant Research (CIBMTR)
.
Biol Blood Marrow Transplant
.
2008
;
14
(
12
):
1323
-
1333
.
63.
Elstrom
RL
,
Martin
P
,
Hurtado Rua
S
, et al
.
Autologous stem cell transplant is feasible in very elderly patients with lymphoma and limited comorbidity
.
Am J Hematol
.
2012
;
87
(
4
):
433
-
435
.
64.
Andorsky
DJ
,
Cohen
M
,
Naeim
A
,
Pinter-Brown
L
.
Outcomes of auto-SCT for lymphoma in subjects aged 70 years and over
.
Bone Marrow Transplant
.
2011
;
46
(
9
):
1219
-
1225
.
65.
Locke
FL
,
Ghobadi
A
,
Jacobson
CA
, et al
.
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial
.
Lancet Oncol
.
2019
;
20
(
1
):
31
-
42
.
66.
Schuster
SJ
,
Bishop
MR
,
Tam
CS
, et al;
JULIET Investigators
.
Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma
.
N Engl J Med
.
2019
;
380
(
1
):
45
-
56
.
67.
Sano
D
,
Nastoupil
LJ
,
Fowler
NH
, et al
.
Safety of axicabtagene ciloleucel CD19 CAR T-cell therapy in elderly patients with relapsed or refractory large B-cell lymphoma
.
Blood
.
2018
;
132
(
suppl 1
):
96
.
68.
Sharma
P
,
Singh
H
,
Bouchkouj
N
,
Krauss
AC
,
George
B
A U.S. Food and Drug Administration age based pooled analysis of cytokine release syndrome and neurotoxicity in subjects with relapsed/refractory lymphoma treated with chimeric antigen receptor (CAR) T cell therapy
.
Blood
.
2018
;
132
(
suppl 1
):
4201
.
You do not currently have access to this content.